Vaginal DrynessPhase 3NCT02638337
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
A Phase 3 study testing Ospemifene in people with Vaginal Dryness, run by Shionogi.
Trial summary
The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA. Read more about this study
- Who is it for?
- Ages 40 to 80 years, women only
- Conditions the study is for
- Vaginal Dryness
- What is being tested?
- Ospemifene
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 631 participants
- Where
- No sites listed yet
- Study dates
- 26 Jan 2016to 5 Jul 2017
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject is postmenopausal.
- Subject has moderate to severe vaginal dryness as the self-reported MBS of VVA.
Who cannot join
- Subject has clinically significant abnormal findings in the physical examination.
- Subject has a body mass index (BMI) equal to or greater than 38 kg/m^2
- Subject has uncontrolled hypertension.
- Subject has clinically significant abnormal findings in the gynecological examination other than signs of vaginal atrophy.
- Subject has uterine/vaginal bleeding of unknown origin.
- Subject has a vaginal infection requiring medication (may be treated and be eligible for study).
About this study
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause
The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.
- Conditions
- Vaginal Dryness
- Being tested
- Ospemifene, Placebo
- Keywords
- Vulvo-vaginal Atrophy, menopause
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OspemifeneDrug
Also called Osphena®
60 mg tablet
PlaceboDrug
Tablet identical to the ospemifene tablet without drug
| Study group | Role | What they receive |
|---|---|---|
| Ospemifene | Experimental | Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks. Receives: Drug: Ospemifene |
| Placebo | Placebo comparator | Participants will take one tablet of matching placebo, orally, once a day for 12 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12
Parabasal cells are immature squamous cells in the lining of the vagina. A predominance of parabasal cells indicates absence of estrogenic stimulation and vaginal atrophy.
Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist.
A decrease in parabasal cells indicates improvement in vaginal atrophy. To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Measured: Baseline and Week 12
Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Week 12
Superficial cells are mature squamous cells in the lining of the vagina that can decrease in number after menopause resulting in vulvovaginal atrophy.
Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist.
An increase in the number of superficial cells indicates improvement in atrophy.
To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Measured: Baseline and Week 12
Change From Baseline in the Vaginal pH at Week 12
The pH scale ranges from 0 to 14. A pH of 7 is neutral, less than 7 is acidic, and greater than 7 is basic. A typical vaginal pH in women of reproductive age is between 3.5 and 4.5, increasing to > 4.5 after menopause.
Vaginal pH was measured by the investigator using a pH indicator strip at the middle third of the vaginal wall.
To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Measured: Baseline and Week 12
Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Week 12
The severity of the most bothersome symptom of vaginal dryness was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3.
Measured: Baseline and Week 12
Number of Participants With Adverse Events
Treatment-related adverse events (AEs) were defined as AEs that were considered by the investigator to be related to investigational medicinal product, for which causal relationship with the study drug could be reasonably explained.
A serious adverse event (SAE) is defined as any AE occurring at any dose that resulted in any of the following outcomes:
- Death
- Life-threatening condition
- Hospitalization or prolongation of existing hospitalization for treatment
- Persistent or significant disability/incapacity
- Congenital anomaly/birth defect
- Other medically important conditions that, based on medical judgment, may jeopardize the participant's health and may require medical intervention to prevent one of the outcomes listed above.
Measured: From the first dose of study drug up to 14 days after the last dose; 14 weeks
Secondary outcomes (34)
Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Weeks 4 and 8
Parabasal cells are immature squamous cells in the lining of the vagina. A predominance of parabasal cells indicates absence of estrogenic stimulation and vaginal atrophy. Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist. A decrease in parabasal cells indicates improvement in vaginal atrophy.
Measured: Baseline and Weeks 4 and 8
Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Weeks 4 and 8
Superficial cells are mature squamous cells in the lining of the vagina that can decrease in number after menopause resulting in vulvovaginal atrophy. Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist. An increase in the number of superficial cells indicates improvement in atrophy.
Measured: Baseline and Weeks 4 and 8
Change From Baseline in the Vaginal pH
The pH scale ranges from 0 to 14. A pH of 7 is neutral, less than 7 is acidic, and greater than 7 is basic. A typical vaginal pH in women of reproductive age is between 3.5 and 4.5, increasing to > 4.5 after menopause. Vaginal pH was measured by the investigator using a pH indicator strip at the middle third of the vaginal wall.
Measured: Baseline and Weeks 4 and 8
Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Weeks 4 and 8
The severity of the most bothersome symptom of vaginal dryness was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3.
Measured: Baseline and Weeks 4 and 8
Change From Baseline in Vaginal and/or Vulvar Irritation or Itching
The severity of vaginal and/or vulvar irritation or itching was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3.
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Difficult or Painful Urination
The severity of difficult or painful urination was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3.
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vaginal Pain Associated With Sexual Activity
The severity of vaginal pain associated with sexual activity was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3.
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vaginal Bleeding Associated With Sexual Activity
The severity of vaginal bleeding associated with sexual activity was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3.
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Maturation Value
The maturation value is an indicator of the level of maturation attained by the vaginal epithelium.
Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at the central laboratory by a qualified pathologist. Parabasal cells (P), intermediary cells (I), and superficial cells (S) were counted and results were expressed as the maturation value (MV), whereby superficial cells were assigned a point value of 1.0, intermediate cells were assigned a point value of 0.5, and parabasal cells were assigned a point value of 0. The maturation value (MV) was defined as:
(percentage of superficial cells * 1) + (percentage of intermediate cells * 0.5) + (percentage of parabasal calls * 0).
Lower MV indicates lower estrogen effect.
Measured: Baseline and Weeks 4, 8, and 12
Percentage of Participants Who Were Responders at Week 4, Week 8, and Week 12
A participant was defined as a responder if all the following conditions were met::
- Increase from baseline in maturation value of at least 10
- Decrease from baseline in vaginal pH of at least 0.5
- Improvement from baseline (decrease in severity) of at least 1 point in the most bothersome symptom of vaginal dryness
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vaginal Health Index
The investigator performed an evaluation of the vagina, assessing overall elasticity, fluid secretion, pH, condition of epithelial mucosa, and moisture. The severity of each characteristic was assessed using a 5-grade scale from 1 (worst) to 5 (best). The total score was calculated as the sum of the 5 individual scores and ranges from 5 to 25, where higher scores indicate better vaginal health
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vulvar Health Index
The investigator performed a visual examination of the vulva, assessing the labia majora, labia minora, clitoris, introitus appearance and elasticity, color, discomfort and pain, and presence of other findings (eg, petechiae, excoriations, ulcers, etc). The severity of each characteristic was assessed on a 4-point scale as 0 = normal, 1 = mild, 2 = moderate, and 3 = severe. The total score was calculated by adding the 7 individual scores and ranges from 0 to 21, where lower scores indicate better vulvar health. A negative change from baseline indicates improvement.
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vulvovaginal Imaging Total Score at Week 12
Vulvovaginal imaging was performed by trained site personnel following a standard procedure. Photographs were assessed by an Independent Panel Review (IPR) in a blinded fashion. Nine parameters (labia majora, labia minora, clitoris, urethra, introitus and elasticity, color, erythema, moisture, and other findings (petechiae, excoriation, ulceration, etc.)) were evaluated on a scale from 0 (normal/none) to 3 (severe). The total score was calculated from the sum of the 9 individual scores and ranged from 0 to 27 with lower values indicating better vulvovaginal health; a negative change from baseline indicates improvement.
Measured: Baseline and Week 12
Change From Baseline in Female Sexual Function Index Total Score
The Female Sexual Function Index consists of 19 questions organized into 6 domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) answered by the participant on a 5-point scale from 1 to 5. Where relevant, some questions also include an option of 0 if a question is not applicable due to no sexual activity. Each domain score was calculated by adding the scores of each item in the domain and multiplying by a domain factor. The total score was calculated by summing each domain score and ranges from 2 to 36, with higher values indicating better sexual function.
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Female Sexual Function Index Domain Scores at Week 12
The Female Sexual Function Index consists of 19 questions, organized into 6 domains (desire, arousal, lubrication, orgasm, satisfaction, and pain), answered by the participant on a scale from 1 to 5. Where relevant, some questions also include an option of 0 if not applicable due to no sexual activity. Each domain score was calculated by adding the scores of each item in the domain and multiplying by a domain factor. For all domains, higher values indicate better sexual function, according to the following:
Desire (2 questions): domain score ranges from 1.2 to 6; Arousal (4 questions): domain score ranges from 0 to 6; Lubrication (4 questions): domain score ranges from 0 to 6; Orgasm (3 questions): domain score ranges from 0 to 6; Satisfaction (3 questions): domain score ranges from 0.8 to 6; Pain (3 questions): domain score ranges from 0 to 6.
Measured: Baseline and Week 12
Change From Baseline in Urinary Distress Inventory (UDI)-6 Total Score
The presence or absence of urinary symptoms was assessed using the Urinary Distress Inventory (UDI)-6. The symptoms include frequent urination, urine leakage related to the feeling of urgency, urine leakage related to physical activity, coughing, or sneezing, small amounts of urine leakage, difficulty emptying bladder, and pain and discomfort in the lower abdominal or genital area. If a symptom was present, participants were asked to assess the degree to which they were bothered by it on the following 4-point scale:
- = present but doesn't bother her at all;
- = present and bothers her slightly;
- = present and bothers her moderately;
- = present and bothers her greatly. The total score was calculated by adding the 6 scores together (Absent = 0), and ranges from 0 to 24, with lower values indicating less urinary distress.
Measured: Baseline and Weeks 4, 8, and 12
Change From Baseline in Bone Sialoprotein at Week 12
Serum bone sialoprotein (BSP) was measured as a marker of bone resorption.
Measured: Baseline and Week 12
Change From Baseline in Type I Collagen C-Telopeptide (CTX) at Week 12
Type I collagen C-telopeptide was measured as a marker of bone resorption.
Measured: Baseline and Week 12
Change From Baseline in Deoxypyridinoline at Week 12
Deoxypyridinoline was measured as a marker of bone resorption.
Measured: Baseline and Week 12
Change From Baseline in Type I Collagen N-Telopeptide (NTX) at Week 12
Type I collagen N-telopeptide was measured as a marker of bone resorption.
Measured: Baseline and Week 12
Change From Baseline in Tartrate-Resistant Acid Phosphatase 5b at Week 12
Tartrate-resistant acid phosphatase 5b was measured as a marker of bone resorption.
Measured: Baseline and Week 12
Change From Baseline in Alkaline Phosphatase at Week 12
Alkaline phosphatase was measured as a marker of bone formation.
Measured: Baseline and Week 12
Change From Baseline in Bone-specific Alkaline Phosphatase at Week 12
Bone-specific alkaline phosphatase was measured as a marker of bone formation.
Measured: Baseline and Week 12
Change From Baseline in Osteocalcin at Week 12
Osteocalcin was measured as a marker for bone formation.
Measured: Baseline and Week 12
Change From Baseline in Procollagen 1 N-Terminal Propeptide (P1NP) at Week 12
Procollagen 1 N-terminal propeptide was measured as a marker of bone formation.
Measured: Baseline and Week 12
Mean Days of Lubricant Use Per Week
The mean number of days/week that lubricant was used as documented by participants in an electronic daily diary.
Measured: Week 1 to Week 12
Mean Days of Intercourse Per Week
The mean number of days/week of intercourse as recorded by participants in an electronic daily diary.
Measured: Week 1 to Week 12
Overall Satisfaction With Treatment at Week 12
Participants were asked to record their overall satisfaction with treatment in an electronic diary according to the following categories: Very satisfied, Moderately satisfied, About equally satisfied and dissatisfied, Moderately dissatisfied, and Very dissatisfied.
Measured: Week 12
Change From Baseline in Estradiol at Week 12
Measured: Baseline and Week 12
Change From Baseline in Follicle-Stimulating Hormone at Week 12
Measured: Baseline and Week 12
Change From Baseline in Luteinizing Hormone at Week 12
Measured: Baseline and Week 12
Change From Baseline in Sex Hormone-Binding Globulin at Week 12
Measured: Baseline and Week 12
Change From Baseline in Testosterone at Week 12
Measured: Baseline and Week 12
Change From Baseline in Free Testosterone at Week 12
Measured: Baseline and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2015 (estimated)
- Study start26 Jan 2016
- Primary completion23 Jun 2017
- Study completion5 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Vaginal DrynessStudies of the same condition, open and under way.
- More trials run by ShionogiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 631 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shionogi
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Shionogi Clinical Trials Administrator Clinical Support Help Line, Study director, Shionogi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02638337
- Sponsor's protocol ID
- 1517I0231
- Status last verified
- Mar 2019
- First submitted
- 18 Dec 2015
- Last updated
- 2 Apr 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Lara LA, Cartagena-Ramos D, Figueiredo JB, Rosa-E-Silva ACJ, Ferriani RA, Martins WP, Fuentealba-Torres M. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2023 Aug 24;8(8):CD009672. doi: 10.1002/14651858.CD009672.pub3.
PubMed 37619252Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019 Jan 28;26(6):611-621. doi: 10.1097/GME.0000000000001292.
PubMed 30694917
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause
- ClinicalTrials.gov ID
- NCT02638337
- Acronym / sponsor ID
- 1517I0231
- Conditions
- Vaginal Dryness
- Keywords
- Vulvo-vaginal Atrophy, menopause
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 631 participants (actual)
- Lead sponsor
- ShionogiIndustry (pharma, biotech, devices)
- Study start
- 26 Jan 2016 (actual)
- Primary completion
- 23 Jun 2017 (actual)
- Study completion
- 5 Jul 2017 (actual)
- First posted
- 23 Dec 2015 (estimated)
- Results
- Posted 2 Apr 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ospemifene | Experimental | Drug: OspemifeneParticipants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will take one tablet of matching placebo, orally, once a day for 12 weeks. |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Subject is postmenopausal.
- Subject has moderate to severe vaginal dryness as the self-reported MBS of VVA.
Key exclusion criteria (6 listed)
- Subject has clinically significant abnormal findings in the physical examination.
- Subject has a body mass index (BMI) equal to or greater than 38 kg/m^2
- Subject has uncontrolled hypertension.
- Subject has clinically significant abnormal findings in the gynecological examination other than signs of vaginal atrophy.
- Subject has uterine/vaginal bleeding of unknown origin.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OspemifeneAlso: Osphena®60 mg tablet | Drug | Ospemifene |
| PlaceboTablet identical to the ospemifene tablet without drug | Drug | Placebo |
Primary outcome
Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12
Time frame: Baseline and Week 12
Parabasal cells are immature squamous cells in the lining of the vagina. A predominance of parabasal cells indicates absence of estrogenic stimulation and vaginal atrophy. Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist. A decrease in parabasal cells indicates improvement in vaginal atrophy. To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Week 12
Time frame: Baseline and Week 12
Superficial cells are mature squamous cells in the lining of the vagina that can decrease in number after menopause resulting in vulvovaginal atrophy. Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist. An increase in the number of superficial cells indicates improvement in atrophy. To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Change From Baseline in the Vaginal pH at Week 12
Time frame: Baseline and Week 12
The pH scale ranges from 0 to 14. A pH of 7 is neutral, less than 7 is acidic, and greater than 7 is basic. A typical vaginal pH in women of reproductive age is between 3.5 and 4.5, increasing to > 4.5 after menopause. Vaginal pH was measured by the investigator using a pH indicator strip at the middle third of the vaginal wall. To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Week 12
Time frame: Baseline and Week 12
The severity of the most bothersome symptom of vaginal dryness was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3.
Number of Participants With Adverse Events
Time frame: From the first dose of study drug up to 14 days after the last dose; 14 weeks
Treatment-related adverse events (AEs) were defined as AEs that were considered by the investigator to be related to investigational medicinal product, for which causal relationship with the study drug could be reasonably explained. A serious adverse event (SAE) is defined as any AE occurring at any dose that resulted in any of the following outcomes: * Death * Life-threatening condition * Hospitalization or prolongation of existing hospitalization for treatment * Persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important conditions that, based on medical judgment, may jeopardize the participant's health and may require medical intervention to prevent one of the outcomes listed above.
34 secondary outcomes
Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Weeks 4 and 8
Time frame: Baseline and Weeks 4 and 8
Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Weeks 4 and 8
Time frame: Baseline and Weeks 4 and 8
Change From Baseline in the Vaginal pH
Time frame: Baseline and Weeks 4 and 8
Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Weeks 4 and 8
Time frame: Baseline and Weeks 4 and 8
Change From Baseline in Vaginal and/or Vulvar Irritation or Itching
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Difficult or Painful Urination
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vaginal Pain Associated With Sexual Activity
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vaginal Bleeding Associated With Sexual Activity
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Maturation Value
Time frame: Baseline and Weeks 4, 8, and 12
Percentage of Participants Who Were Responders at Week 4, Week 8, and Week 12
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vaginal Health Index
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vulvar Health Index
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Vulvovaginal Imaging Total Score at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Female Sexual Function Index Total Score
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Female Sexual Function Index Domain Scores at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Urinary Distress Inventory (UDI)-6 Total Score
Time frame: Baseline and Weeks 4, 8, and 12
Change From Baseline in Bone Sialoprotein at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Type I Collagen C-Telopeptide (CTX) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Deoxypyridinoline at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Type I Collagen N-Telopeptide (NTX) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Tartrate-Resistant Acid Phosphatase 5b at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Alkaline Phosphatase at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Bone-specific Alkaline Phosphatase at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Osteocalcin at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Procollagen 1 N-Terminal Propeptide (P1NP) at Week 12
Time frame: Baseline and Week 12
Mean Days of Lubricant Use Per Week
Time frame: Week 1 to Week 12
Mean Days of Intercourse Per Week
Time frame: Week 1 to Week 12
Overall Satisfaction With Treatment at Week 12
Time frame: Week 12
Change From Baseline in Estradiol at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Follicle-Stimulating Hormone at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Luteinizing Hormone at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Sex Hormone-Binding Globulin at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Testosterone at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Free Testosterone at Week 12
Time frame: Baseline and Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37619252Lara LA, Cartagena-Ramos D, Figueiredo JB, Rosa-E-Silva ACJ, Ferriani RA, Martins WP, Fuentealba-Torres M. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2023 Aug 24;8(8):CD009672. doi: 10.1002/14651858.CD009672.pub3.
- Derived from this study: PubMed 30694917Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019 Jan 28;26(6):611-621. doi: 10.1097/GME.0000000000001292.
Related trials for Vaginal Dryness
Not yet recruiting
A Clinical Trial to Evaluate the Effects of the NeuEve Dryness Treatment Kit on Vaginal Health, Comfort, and Quality of Life in Postmenopausal Women
Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin)
Recruiting
Exploration of the Effect of a Wheat Polar Lipid Complex on Vaginal Dryness in Healthy Postmenopausal Women
Vaginal Dryness, Menopause Symptoms
RecruitingPhase 2
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Vulvo Vaginal Atrophy (VVA)
RecruitingPhase 3
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
Vaginal Atrophy, Breast Carcinoma
Recruiting
F-GYN for Vaginal Dryness and Vulvovaginal Atrophy
Atrophic Vaginitis, Atrophic Vulvovaginitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shionogi Clinical Trials Administrator Clinical Support Help Line study director
Shionogi
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ospemifene in people with Vaginal Dryness, run by Shionogi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Apr 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12 (time frame: Baseline and Week 12). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02638337, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2019.